HETLIOZ Demonstrates Significant Sleep Improvement in Primary Insomnia Trial Published in PLOS One
核心洞察
HETLIOZ (tasimelteon) met its primary endpoint in a multicenter, randomized, double-blind, placebo-controlled trial, showing significant improvements in sleep latency for patients with primary insomnia (搜索).
The melatonin receptor (搜索) agonist demonstrated mean improvements in latency to persistent sleep of 44.9 minutes (20 mg dose) and 46.3 minutes (50 mg dose) versus 28.2 minutes for placebo (p < 0.001).
The drug showed sustained efficacy through follow-up time points and was not associated with cognitive or mood changes, rebound, or withdrawal effects after discontinuation.
Vanda Pharmaceuticals announced the publication of positive results from a multicenter, randomized, double-blind, placebo-controlled trial of HETLIOZ (tasimelteon) in patients with primary insomnia (搜索), with findings published in PLOS One on September 24, 2025.
Primary Endpoint Achievement
The study demonstrated that HETLIOZ met its primary endpoint, showing statistically significant improvements in latency to persistent sleep (LPS) compared to placebo. Patients receiving the 20 mg dose experienced a mean improvement of 44.9 minutes from baseline to the average of Nights 1 and 8, while those on the 50 mg dose showed a 46.3-minute improvement. In contrast, the placebo group demonstrated only a 28.2-minute improvement (p < 0.001).
The therapeutic benefits persisted beyond the initial treatment period, with improvements in LPS maintained through follow-up time points at Nights 22 and 29 (p < 0.01).
Safety and Tolerability Profile
The trial revealed a favorable safety profile for HETLIOZ. The drug was not associated with cognitive or mood changes during treatment. Importantly, researchers observed neither rebound nor withdrawal effects after discontinuation, addressing common concerns associated with sleep medications.
Clinical Context and Unmet Need
Insomnia (搜索) represents a significant public health challenge, affecting over 10% of the American population and causing substantial morbidity and next-day consequences. The condition remains a significant health problem for Americans, highlighting the need for effective therapeutic interventions.
Current Regulatory Status and Development Pipeline
HETLIOZ is currently approved as a melatonin receptor (搜索) agonist and circadian regulator for treating Non-24-Hour Sleep-Wake Disorder (搜索) in adults and nighttime sleep disturbances in adults and children with Smith-Magenis Syndrome (搜索).
Vanda Pharmaceuticals is actively pursuing U.S. Food and Drug Administration approval for HETLIOZ in the treatment of insomnia (搜索) and Jet Lag Disorder (搜索). The company is also continuing development of the drug for several other sleep disorders, including Delayed Sleep Phase Disorder (搜索) and pediatric insomnia.
Study Publication Details
The complete study, authored by Synnott NC, Polymeropoulos CM, Xiao C, Birznieks G, and Polymeropoulos MH, is available in PLOS One with the DOI: https://doi.org/10.1371/journal.pone.0332366. The research represents a significant step forward in addressing the therapeutic needs of patients with primary insomnia (搜索) through a mechanistically distinct approach targeting melatonin receptors and circadian regulation.